Your Health Product Claim Is Clear. But Can Buyers See the Value Behind It?
Repeated buyer questions can show you where your value proposition is creating friction—and whether the right fix is better content, sharper positioning, clearer implementation or something outside Marketing altogether.
A longevity platform describes its product as delivering “personalised insights.”
The claim is accurate. The platform combines blood biomarkers, lifestyle information and wearable data to generate recommendations for each user.
Then Sales has to explain what is actually personalised…
Prospects want to know how the recommendations differ from advice they could find elsewhere.
Customers ask why a particular recommendation applies to them.
Customer Success provides more context after purchase.
Marketing creates an FAQ, an explainer and another sales asset to make the distinction clearer.
At some point, the question should change:
Is this really a content gap, or is the need for constant clarification telling us where the value proposition stops doing its job?
A product claim can be technically accurate and still create commercial friction if the buyer cannot connect it to something they can recognise, evaluate or act on. When different teams repeatedly have to complete that connection, those conversations become useful evidence.
The question is no longer simply, “What content should we create?” It is: What does someone still have to clarify before the value becomes clear—and why?
The questions that follow the claim are part of your marketing evidence
Consider three familiar digital health promises: personalised, actionable and comprehensive. Each can describe something genuinely valuable. But each can leave a different part of that value unresolved.
Take a longevity platform that analyses blood biomarkers, sleep, activity and lifestyle data to generate personalised recommendations. The methodology genuinely uses individual information. But suppose the customer ultimately receives familiar advice about sleep, exercise and nutrition.
The recurring question becomes: What changed because of my data? The customer may understand that personalisation occurred technically without being able to see its consequence.
Now consider a remote-monitoring platform promising “actionable insights.” It detects changes in patient data and generates alerts. Buyers understand the capability. Yet Sales repeatedly has to clarify who receives the alert, which alerts require review, what information the clinician sees and what happens next.
The unresolved question is different: What does this change in our workflow?
“Comprehensive insights” can create another problem. A longevity product might combine blood tests, wearable data, family history and lifestyle information in one assessment. A prospect can see that the product considers more inputs than a standard health check. But that breadth does not automatically tell them what becomes easier to understand or decide as a result.
Here the question is: What becomes possible because these inputs are considered together?
These are not three versions of the same messaging problem. One concerns whether differentiation is visible. Another concerns operational consequence. Another concerns whether breadth translates into useful decision support.
That distinction matters because they may require different fixes.
Different recurring questions point to different problems
When the same question keeps appearing in Sales calls, onboarding conversations, support tickets or Customer Success feedback, the instinct is often to turn it into a content request.
Sometimes that is exactly right. If prospects need information that already exists but is difficult to find or understand, a clearer page, implementation guide, case study or sales asset may solve the problem.
But recurring questions can point somewhere else. If customers keep asking what makes a longevity programme “personalised” because they cannot see how their biomarkers or wearable data affect the recommendations, the missing proof may sit in the product experience.
If healthcare buyers understand that a platform generates clinical alerts but cannot determine what adopting it will require from their team, the missing layer may be implementation.
If a broad promise such as “comprehensive” could apply equally well to several competitors, the problem may be positioning rather than explanation.
If a health claim cannot be made more decisive without going beyond what the evidence supports, the constraint is not weak copy. It is the evidence boundary.
And sometimes the clarification is not a defect at all. A clinician interpreting complex findings or a health professional helping someone understand what those findings mean in context may be part of the service’s value.
The objective, then, is not to eliminate explanation. It is to understand what kind of clarification keeps being required, and where it belongs.
That changes the decision from “What should we publish?” to “What actually needs to change?”
In B2B health, buyers are evaluating the work they inherit
This distinction becomes especially important when the buyer is not the end user. Imagine a healthcare provider evaluating a remote-monitoring platform.
The vendor demonstrates continuous monitoring, intelligent alerts and earlier identification of potential problems. The capability is attractive.
The buyer starts asking questions:
- Who monitors the alerts?
- How many should we expect?
- Which require action?
- Does a clinician need to review them?
- What happens outside working hours?
- How does this integrate with existing systems?
- Will it remove work somewhere, or create another queue somebody has to manage?
These can sound like implementation questions that belong later in the buying process. They may actually be part of the buying case.
A 2026 systematic review covering 204 empirical studies across 23 high-income countries found that digital-health implementation in primary care depended on interacting technological, organisational and policy conditions. Implementation was more likely when tools were perceived as usable and offered clear clinical or operational advantage; it could stall when tools added workload, staffing or financial support was inadequate, or IT systems were fragmented.
That evidence does not mean a communications team can solve implementation problems. But it helps explain why a healthcare buyer may not evaluate “AI-powered clinical insights” solely by asking whether the technology can generate them.
They are also evaluating what happens because the insight exists. Who receives it? What decision does it inform? What work changes? What burden disappears? What new responsibility appears?
For B2B digital health, the operational consequence of a capability can therefore be part of its commercial value.
The homepage does not need to become an implementation manual. But if Sales has to reconstruct that connection from scratch in every conversation, an important part of the buying story may be arriving too late.
Some explanation is friction. Some explanation is the value
There is a risk in taking this argument too far. A strong value proposition does not mean every question should disappear before a prospect speaks to Sales.
Complex B2B health products require explanation. Responsible buyers should ask detailed questions. Clinical and operational decisions often depend on context.
Health information also does not always support a simple action. Consider a longevity platform that identifies an unusual biomarker result. The responsible next step may be further testing, monitoring or discussion with a qualified healthcare professional—not an automated instruction telling the user exactly what to do.
Making the recommendation sound more “actionable” would not necessarily improve the product promise. It could make it less defensible. This is why “actionable” needs particular care in health marketing.
A useful test is not whether every output ends with an instruction. It is whether the product helps the appropriate person understand what, if anything, should happen next without implying more certainty than the evidence supports.
The same principle applies beyond scientific claims. Some questions persist because the communications are incomplete. Others reveal implementation complexity. Some require Product involvement. Others require clinical judgment. And some belong in Sales because the answer depends on the buyer’s organisation.
The goal is not self-explanatory marketing at any cost. It is to stop using more content to compensate for unresolved problems elsewhere.
Decide what is broken before you produce the fix
Suppose customers repeatedly ask why a company’s longevity recommendations are personalised. One response is to publish a detailed article explaining the methodology. That may be the right intervention if the information exists but is difficult to find.
But suppose customers provide blood results, wearable data and detailed lifestyle information, yet still receive recommendations they perceive as generic. A methodology article may prove that personalisation happens technically without making its practical value more visible.
The company could end up producing increasingly detailed content around a question the product experience keeps recreating. The same thing can happen with “actionable insights.” If buyers repeatedly ask who receives an alert, what they need to do, and how much work it creates, another article about the benefits of actionable data may add very little.
A workflow example might help, same as an implementation case study, more precise positioning, a different sales tool or a Product change. The important decision comes before the asset: Where should this missing connection actually be solved?
That question prevents the content team from becoming the default destination for every unresolved question around the product. It also protects the business from investing in more assets when content is not the constraint.
Audit the explanation around your strongest claims
Start with the few promises carrying the most weight in your value proposition: perhaps personalised, actionable, comprehensive, integrated, efficient or AI-powered. Then follow each one beyond the website.
First, ask what the claim requires the buyer to believe.
“Personalised” should imply that something meaningful changes because of individual information. “Efficient” should make clear whose work becomes easier. “Actionable” should establish who can do what differently.
Next, find where the buyer can see the proof.
Not where the company says the claim is true, but where the product, service, evidence or implementation experience makes the promised benefit recognisable.
Then look at what someone still has to add.
Review Sales calls, objections, onboarding questions, support conversations and implementation discussions. Look for clarification that keeps recurring after the headline promise has already been communicated.
Finally, ask the question that determines the investment: Where should that missing connection be resolved?
- If the information exists but is hard to find, improve the content.
- If the promise is too broad to communicate meaningful differentiation, revisit the positioning.
- If buyers cannot see how the capability changes their workflow, strengthen the implementation story.
- If the benefit is difficult to recognise in the experience itself, involve Product.
- If stronger wording would exceed the evidence, respect the evidence boundary.
- If interpretation genuinely requires professional expertise or buyer-specific context, keep the human explanation where it adds value.
The output of this audit should not automatically be another content brief. It should be a better decision about what deserves fixing.
A strong claim should survive contact with the buying experience
B2B digital health marketers have a difficult job. They need to make complex products understandable without stripping away the clinical, technical and operational detail that makes them credible.
Broad claims help compress that complexity: “personalised,” “actionable,” “comprehensive,” “AI-powered.” But the real test comes after the claim leaves the marketing deck.
- What does Sales still have to add before a prospect understands why the capability matters?
- What does the buyer still have to translate from feature into consequence?
- And where should that missing connection actually be solved?
Those questions turn recurring explanations from an endless source of content requests into something more useful: evidence about how well the value proposition holds together across the buying experience.
Sometimes the answer will be better content. Sometimes, it will be more precise positioning, clearer implementation guidance, stronger evidence, a change in the product experience or deliberate human interpretation.
Knowing the difference matters because the content team’s job is not to produce enough explanation to make any claim work. It is to make the right parts of the value clear—and recognise when the problem belongs somewhere else.
If your digital health company has strong expertise, evidence or product value but struggles to turn it into clear, credible content that helps buyers understand why it matters, this is the kind of problem I work on: connecting evidence, product value and buyer questions so Marketing has stronger material to work with and Sales has less explaining to do.
